ArticleEuropean heart journal. Digital health2026
Signal artefacts in wearable-based biosignal acquisition in patients with ventricular assist devices: the SMART-VADCH trial.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Telemonitoring is increasingly used in cardiovascular care, yet data on the reliability of smartwatch-based biosignal acquisition in patients with advanced heart failure and LVAD support remain limited. This study evaluated the feasibility and accuracy of smartwatch-derived heart rate (HR), oxygen saturation (SpO Methods and results: In this prospective, single-centre pilot study, patients without LVAD or with durable (HeartMate 3) or temporary (Impella 5.5) LVADs underwent parallel resting measurements using a consumer smartwatch and standard clinical. Measurements unsuccessful after three attempts were classified as failures. Thirty-eight patients were enrolled (15 heart failure, 15 durable LVAD, 8 temporary LVAD). In patients without LVAD, HR was feasible in all patients and accurate within a 5% tolerance in 93% (95% CI 70-99%). At least one interpretable ECG was obtained in all, although QRS duration met a 10% tolerance in 33%. SpO₂ was feasible and accurate in 93%. In LVAD, HR was feasible in all patients and accurate in 82%. ECG was technically successful in all. QRS complexes were distinguishable in 73% of durable and all temporary LVAD. SpO₂ feasibility was overall limited (36%), but higher in temporary than durable LVAD patients (63% vs. 20%), and accurate when successful. SpO₂ failure was observed in patients without aortic valve opening, with tachycardia >100 bpm, and with darkly pigmented skin. Conclusion: The evaluated wrist-worn smartwatch reliably provided HR and ECG measurements in advanced heart failure, including LVAD patients, whereas SpO₂ performance remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.